Key considerations for maximizing LV and AAV production in transient transfection workflows
Cell & Gene Therapy Insights 2021; 7(9), 1047–1064
Published: 8 October 2021
Recombinant adeno-associated virus (AAV) and lentivirus (LV) are essential components of gene and cell therapies, which show incredible promise for the treatment of genetic and acquired diseases. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. In this article, critical parameters for optimizing viral vector production are discussed, along with how TransIT-VirusGEN® Transfection Reagent and accompanying enhancer components can support manufacturers from research and development through commercial manufacturing.